Vascular Pharmaceuticals Careers in Chapel Hill, NC

Venture backed, pre-clinical stage biotechnology company. Our development efforts are focused on VPI-2690B, which targets a pathway that is stimulated by hyperglycemia. In multiple animal studies, VPI-2690B has been shown to slow the development of diabetic complications including nephropathy, accelerated atherosclerosis and retinopathy. focused on the development and commercialization of novel therapeutic products for the treatment of cardiovascular and metabolic complications related to diabetes. Vascular won of the 2010 SE BIO Early Stage Company competition and following the close of of Series A round and parallel transaction with Janssen Biotech, was awarded the SE BIO 2012 Initial Investment and Strategic Investment awards. Vascular expects to file our first IND and commence human clinical trials during the 4th quarter of 2013. Specialties Biotechnology